Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04149353 · ClinicalTrials.gov registry record · NA
PET/MR in Surgical Planning for Breast CA Treated With Neoadj Chemo
A NA study, sponsored by UNC Lineberger Comprehensive Cancer Center.
- Terminated
- Registry status
- NA
- Development phase
- 1
- Enrollment target
NCT04149353 is a NA study that was terminated before completion, run by UNC Lineberger Comprehensive Cancer Center. The registered enrollment target is 1 participants.
The verdict
NCT04149353, a NA study, was terminated before completion, sponsored by UNC Lineberger Comprehensive Cancer Center.
- TERMINATED
- Registry status
- NA
- Development phase
- 1 participants
- Enrollment target
Study Summary
Purpose: To assess the utility of combined, simultaneous positron emission tomography (PET) and magnetic resonance imaging (MRI), collectively called PET-MR, in assessing response to neoadjuvant chemotherapy and surgical treatment decisions for operable breast cancers. Participants: Adult patients with operable breast cancer that are being treated at UNC with neoadjuvant chemotherapy followed by potentially curative surgical resection. Procedures (methods): Patients who are being treated with neoadjuvant chemotherapy followed by surgical resection and for whom pre- and post-treatment MR imaging is part of planned treatment will undergo additional pre-treatment and post-treatment PET/MR. The response to treatment will be assessed at post-treatment by evaluating change in tumor size from MRI, change in response to dynamic contrast enhanced (DCE) MRI, and 18F-fluorodeoxyglucose (18F-FDG) avidity from PET. Patients will then undergo surgery. Their pathology will be reviewed for treatment effect as assessed by residual cancer burden (RCB) score. Patients will be followed and assessed for recurrence.
Interventions
- DIAGNOSTIC_TEST PET/MR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2018-12-05 |
| Est. Completion | 2020-02-17 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04149353
The ClinicalTrials.gov registry entry for NCT04149353 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UNC Lineberger Comprehensive Cancer Center, which has 366 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PET/MR is the first listed.
NCT04149353 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04149353 about?
NCT04149353 is a clinical study titled "PET/MR in Surgical Planning for Breast CA Treated With Neoadj Chemo". Purpose: To assess the utility of combined, simultaneous positron emission tomography (PET) and magnetic resonance imaging (MRI), collectively called PET-MR, in assessing response to neoadjuvant chemotherapy and surgical treatment decisions for operable breast cancers. Participants: Adult patients ...
What is the current status of trial NCT04149353?
This trial is currently terminated. It is a NA study. The enrollment target is 1 participants. The study started on 2018-12-05. Estimated completion is 2020-02-17.
What interventions are being tested in trial NCT04149353?
The interventions under investigation include: PET/MR (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04149353?
This trial is sponsored by UNC Lineberger Comprehensive Cancer Center, which has 366 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.